Texas NeuroAIDS Research Center

德克萨斯神经艾滋病研究中心

• 批准号: 10818807
• 负责人: BENJAMIN B. GELMAN
• 金额: $ 21.68万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10818807
• 关键词: Autopsy; Biological Assay; Biological Specimen Banks; Blood; Brain; Budgets; Cerebrospinal Fluid; Client; Clinic; Clinical; Clinical Data; Communication; Communities; Contracts; Data; Data Collection; Data Coordinating Center; Discipline of Nursing; Disparity population; Economically Deprived Population; Elderly; Equilibrium; Equipment; Equipment and supply inventories; Funding; Future; HIV; HIV Seropositivity; HIV/AIDS; Human; Institutional Review Boards; Maintenance; Measures; Medical; National NeuroAids Tissue Consortium; Nervous System; Neuropsychology; Notification; Nursing Staff; Patients; Population; Procedures; Process; Repository Operations; Research; Research Personnel; Resources; Safety; Schedule; Services; Site; Source; Specimen; Substance abuse problem; Supervision; Texas; Time; Toxicology; Transportation; Travel; U-Series Cooperative Agreements; United States National Institutes of Health; Visit; Writing; clinical database; clinical research site; cost; human tissue; medical schools; neuroAIDS; operation; opioid overdose; professor; programs; quality assurance; recruit; social disparities; substance use; virology

Abstract This application is for supplemental bridge funding to maintain operation of the Texas NeuroAIDS Research Center (TNRC) for a brief period of time (U24MH10093010). This project recruits HIV positive patients, characterizes them medically and neuropsychologically, performs autopsies when appropriate, maintains a human specimen repository, and distributes specimens worldwide. The funding for fiscal year 5 of this cooperative agreement U24 was to end on February 28, 2023. As of this writing the program is operating on a no cost extension combined with a pending request for “carry forward” funds from prior years that has not yet been approved. The application for continued funding via contracting is under a review by the NIH. According to federal officials the decision regarding funding in the future will not be known for approximately six months from the end of the U24. That has created a “funding gap.” Following the advice of federal officials, we are applying for supplemental bridge funding to maintain normal operations until a decision on long term funds is issued by the NIH. We were advised to apply for funds that will allow operation through August 31, 2023, which amounts to roughly six months of normal operation from the time the U24 was to end. Our request for bridge funds for that period is calculated in a manner suggested by the NIH. We have subtracted from our request two sources of potentially available funds: 1) the balance that was available for an approved no cost extension, and 2) a separate amount corresponding to a pending request for carry forward of unspent funds from prior years. Assuming that these two requests are both approved and enacted by the NIH, we calculated an amount of additional funds necessary to operate through September 1, 2023. That amount is reflected in our budget request and its justification. Supplemental funding is requested to maintain operation until the long-term plan for funding the project become clear.

摘要

项目成果

When do models of NeuroAIDS faithfully imitate "the real thing"?

• DOI: 10.1007/s13365-017-0601-5
• 发表时间: 2018-04
• 期刊: Journal of neurovirology
• 影响因子: 3.2
• 作者: Gelman BB;Endsley J;Kolson D
• 通讯作者: Kolson D

Advancing our understanding of HIV co-infections and neurological disease using the humanized mouse.

• DOI: 10.1186/s12977-021-00559-z
• 发表时间: 2021-06-16
• 期刊: Retrovirology
• 影响因子: 3.3
• 作者: Endsley JJ;Huante MB;Naqvi KF;Gelman BB;Endsley MA
• 通讯作者: Endsley MA

MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology.

• DOI: 10.1371/journal.ppat.1006360
• 发表时间: 2017-06
• 期刊: PLoS pathogens
• 影响因子: 6.7
• 作者: Xu Z;Asahchop EL;Branton WG;Gelman BB;Power C;Hobman TC
• 通讯作者: Hobman TC

Lipocalin-2 mediates HIV-1 induced neuronal injury and behavioral deficits by overriding CCR5-dependent protection.

• DOI: 10.1016/j.bbi.2020.06.016
• 发表时间: 2020-10
• 期刊: Brain, behavior, and immunity
• 作者: Ojeda-Juárez D;Shah R;Fields JA;Harahap-Carrillo IS;Koury J;Maung R;Gelman BB;Baaten BJ;Roberts AJ;Kaul M
• 通讯作者: Kaul M

Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis.

• DOI: 10.1007/s11481-012-9345-4
• 发表时间: 2012-09
• 期刊: JOURNAL OF NEUROIMMUNE PHARMACOLOGY
• 影响因子: 6.2
• 作者: Gelman, Benjamin B.;Lisinicchia, Joshua G.;Chen, Tianshen;Johnson, Kenneth M.;Jennings, Kristofer;Freeman, Daniel H., Jr.;Soukup, Vicki M.
• 通讯作者: Soukup, Vicki M.